142 related articles for article (PubMed ID: 36510653)
21. Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?
Morini MA; Muller RL; de Castro Junior PCB; de Souza RJ; Faria EF
World J Urol; 2018 Aug; 36(8):1225-1231. PubMed ID: 29549484
[TBL] [Abstract][Full Text] [Related]
22. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
23. [Oncological outcomes of prostate cancer surgery].
Soulié M; Salomon L
Prog Urol; 2015 Nov; 25(15):1010-27. PubMed ID: 26519965
[TBL] [Abstract][Full Text] [Related]
24. Comparison of oncological and functional outcomes of pure versus robotic-assisted laparoscopic radical prostatectomy performed by a single surgeon.
Park B; Kim W; Jeong BC; Jeon SS; Lee HM; Choi HY; Seo SI
Scand J Urol; 2013 Feb; 47(1):10-8. PubMed ID: 22835035
[TBL] [Abstract][Full Text] [Related]
25. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy.
Matsuoka Y; Uehara S; Toda K; Fukushima H; Tanaka H; Yoshida S; Yokoyama M; Yoshimura R; Kihara K; Fujii Y
Urol Oncol; 2022 Apr; 40(4):161.e15-161.e23. PubMed ID: 34895818
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of Salvage Robot-assisted Radical Prostatectomy After Focal Ablation for Prostate Cancer in Comparison to Primary Robot-assisted Radical Prostatectomy: A Matched Analysis.
Bhat KRS; Covas Moschovas M; Sandri M; Noel J; Reddy S; Perera R; Rogers T; Roof S; Patel VR
Eur Urol Focus; 2022 Sep; 8(5):1192-1197. PubMed ID: 34736871
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
31. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
32. Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate.
Li X; Xi H; Cheng X; Yu Y; Zhang C; Wang G; Zhou X
Front Endocrinol (Lausanne); 2023; 14():1123934. PubMed ID: 36843605
[TBL] [Abstract][Full Text] [Related]
33. Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial.
Carlsson S; Jäderling F; Wallerstedt A; Nyberg T; Stranne J; Thorsteinsdottir T; Carlsson SV; Bjartell A; Hugosson J; Haglind E; Steineck G
BJU Int; 2016 Aug; 118(2):205-12. PubMed ID: 26867018
[TBL] [Abstract][Full Text] [Related]
34. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract][Full Text] [Related]
35. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Marra G; Valerio M; Heidegger I; Tsaur I; Mathieu R; Ceci F; Ploussard G; van den Bergh RCN; Kretschmer A; Thibault C; Ost P; Tilki D; Kasivisvanathan V; Moschini M; Sanchez-Salas R; Gontero P; Karnes RJ; Montorsi F; Gandaglia G;
Eur Urol Oncol; 2020 Oct; 3(5):565-581. PubMed ID: 32933887
[TBL] [Abstract][Full Text] [Related]
36. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
37. Five-year oncological outcomes of endoscopic extraperitoneal radical prostatectomy (EERPE) for prostate cancer: results from a medium-volume UK centre.
McNeill SA; Good DW; Stewart GD; Stolzenburg JU
BJU Int; 2014 Mar; 113(3):449-57. PubMed ID: 23980640
[TBL] [Abstract][Full Text] [Related]
38. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
39. Comparison of oncological and health-related quality of life outcomes between open and robot-assisted radical prostatectomy for localised prostate cancer - findings from the population-based Victorian Prostate Cancer Registry.
Ong WL; Evans SM; Spelman T; Kearns PA; Murphy DG; Millar JL
BJU Int; 2016 Oct; 118(4):563-9. PubMed ID: 26573954
[TBL] [Abstract][Full Text] [Related]
40. Oncological outcome after radical prostatectomy: Marital status does not make a difference.
Schiffmann J; Beyer B; Tennstedt P; Boehm K; Mehring G; Schlomm T; Salomon G; Karakiewicz P; Graefen M
Int J Urol; 2015 May; 22(5):484-9. PubMed ID: 25781055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
